Fed. Circ. Affirms Celgene Win In Bone Cancer Drug IP Case
The Federal Circuit on Thursday affirmed a lower court decision tossing out patent infringement claims from Andrulis Pharmaceuticals Corp. against rival drugmaker Celgene Corp. over a bone cancer treatment, affirming a...To view the full article, register now.
Already a subscriber? Click here to view full article